|
 TPN introduces a paradigm shift in the market place. The objectives of the Company’s global strategy are based on a clear understanding of the market served as well as on its clients’ need for timely, cost effective and realistic solutions. TPN stays ahead of the curve and customizes the products and/or services to fit every client’s or suppliers specific requirements.
The Company manages and participates directly in the synergies created by contractual agreements with the supplier, the customer or both while adding key products and/or services to the collaboration. Through this proprietary and differentiating business model, TPN focuses on solutions that identify and take advantage of complementary strengths between companies operating in the various segments of the global supply chain. The synergies, created by TPN between U.S., Indian, Chinese and European entities led to the establishment of numerous collaborative relationships, which result in the timely introduction of more cost effective drugs.
The Company provides personalized services and quality expertise; in-depth knowledge and experience of the world’s generic pharma markets; awareness and understanding of international behavior and business practices; and continuous support from its local offices. TPN alone, and/or in collaboration with its clients’ specialized procurement teams, work with contract vendors and suppliers through well established and proven procedures.
TPN’s global network of contacts and partnerships play a central role in developing value driven solutions throughout the supply chain, including intermediates, APIs and finished products sourcing in addition to product development, regulatory, manufacturing, marketing and distribution. The company manages and participates directly in the synergies created through contractual relationships with the supplier, the client or both while adding essential products and/or services to the relationship. Through this unique and differentiating business model TPN focuses on solutions that identify and take advantage of complementary strengths between companies in the API, generic and specialty pharma industry.
TPN’s approach is to enable companies to look beyond their current thought processes and learn to recognize the dynamics of a changing landscape. However, strategy without implementation has little merit, so the Company’s mission includes ensuring that its partners and clients execute these co-developed plans and fully realize their potential through successful execution. Often, TPN identifies market needs and manages value propositions which are structured to provide long term revenue opportunities. In order to reach the set objectives, the Company’s employees work alongside our customers. This results in a more fundamental understanding of the industry, an appreciation of the many factors that make a drive sustainable and how competitive advantages and optimization of product development and distribution efforts lead to greater value creation.
TPN understands that the success of U.S. companies in China and India and Chinese and Indian companies in overseas markets depends heavily on their ability to operate and communicate globally. Hence, the Company provides constructive solutions to help bridge the gap between people from different cultures and fosters relationships between partners with different backgrounds and areas of expertise.
TPN contributes and commits real-world experience and hands-on involvement to every relationship. The Company’s analysis and recommendations, regulatory and drug development know-how as well as its direct access to global sourcing of generic pharmaceuticals and APIs, allow clients to visualize and fully explore and pursue present and future opportunities.
The Company’s product development activities begin with a market assessment analysis, an evaluation of API sourcing options, potential barriers to entry, technical and competitive challenges and a thorough understanding of the overall market dynamics. Although the Company’s primary focus is on generic drugs, other options such as platform technologies, 505(b)2 NDA and Orphan drug prospects are being considered. Currently, TPN is actively involved in the development of tablets, hard and soft gelatin capsules, ophthalmic products and injectables. Other dosage forms such as ointments, creams, liquids and suspensions are also being evaluated.
The Company has established a technology transfer group which includes experts in formulation, analytical methods development, validation and regulatory affairs. These individuals work directly with clients interested in reducing their COGS by transferring existing ANDAs to manufacturing sites in China and India. TPN’s tech transfer group is a proprietary, core competency that is being developed and expanded continuously.
To summarize, the Company’s advantage resides in the strength of its fundamentals (i.e., a thorough knowledge of the markets served, local presence, understanding of global regulatory constraints, flexibility, customized solutions and superior customer service). Every solution proposed is supported by a combination of in-depth research, intimate understanding of a particular market place and a thorough analysis of the costs and time frames involved as well as being tailored to the dynamics and peculiarity of the client’s organization.
|